Pneumonia Clinical Trial
Official title:
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.
This prospective, Phase 2, multi-center, blinded randomized placebo-controlled study is
designed to demonstrate that early treatment with mavrilimumab prevents progression of
respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological
features of hyper-inflammation.
The study population includes patients who have severe pneumonia, defined as hospitalization
due to COVID-19 with abnormal chest imaging and SpO2 <92% on room air or requirement for
supplemental oxygen.
Enrollment: The study will be performed in approximately 4 months total, starting from the
first patient enrolled with enrollment expected to complete within 2 months.
Follow-up Period: The follow-up period is 60 days for each patient enrolled.
A total of 60 patients will be randomized using 1:1 allocation ratio: 30 subjects will
receive mavrilimumab, and 30 subjects will receive placebo infusion. The investigator,
clinical team, and subject will be blinded to treatment assignment.
Participants will be identified by regular review of hospitalized COVID 19 patients to
evaluate for inclusion and exclusion criteria. Participants will then be approached in this
standard manner by study investigator and/or coordinator/research nurse.
Research interventions will take place in the hospital in accordance with privacy standards.
The study team in informed on all study procedures and requirements with daily meetings and
the opportunity to continuously update through secure channels.
In this multicenter consortium of 4 academic centers, each participating site will have their
own IND for patients enrolled at their site. Data collection will occur at each of the 4
academic centers. Data analysis and randomization scheme will be performed by the Cleveland
Clinic C5 Research, data analysis, and randomization scheme will be performed by one site,
Cleveland Clinic C5 Research.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
| Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
| Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
| Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
| Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years
|
Phase 4 | |
| Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
| Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
| Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
| Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
| Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
| Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
| Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
| Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
| Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
| Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
| Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
| Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
| Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A |